chrisvoncsefalvay/vaers-outcomes huggingface dataset:
After the second shot, I have started experiencing short randomly and intermittently dizzy spells similar to Vertigo; This is a spontaneous report from a contactable reporter (Consumer or other non-HCP). The reporter is the patient.  A 51-year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 10Feb2022 at 09:00 (Lot number: FL3196) at the age of 51 years as dose 2, single for COVID-19 immunisation. Relevant medical history included: "None" (unspecified if ongoing). The patient did not receive any concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot number: FL3197, Anatomical location: Left arm, Administration time: 09:00, Route of administration: Unspecified), administration date: 20Jan2022, when the patient was 51 years old, for COVID-19 immunisation.  The following information was reported: DIZZINESS (non-serious) with onset 12Feb2022 at 17:00, outcome "not recovered", described as " After the second shot, I have started experiencing short randomly and intermittently dizzy spells similar to vertigo". Therapeutic measures were not taken as a result of dizziness.  Additional Information: Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.
This spontaneous report has been received from a registered nurse, referring to a female patient of an unknown age. There was no information about the patient's historical conditions, concomitant therapies, drug reaction or allergies provided. On some unspecified dates, the patient was vaccinated with the first dose and second dose of RECOMBIVAX, strength:10/1.0 microgram/ml, via intramuscular, for prophylaxis (anatomical location, lot # and expiration date were not reported). At the reporting time, the nurse inquired if it is alright to give the patient the third dose of their RECOMBIVAX series if the patient has missed the 6 months dose. The patient did not receive the third dose and did not experience any adverse reaction.
None. Pt. was given a KINRIX combo vaccine for a 4 month well child. KINRIX is not given at age less than 4-6 years old.
Pt was given SQ injection of varicella on 03/18/2002 in LUT. Two days later area became red, swollen, and firm to touch. Mom did nightly warm tub baths, applied neosporin.
Shortness of breath, weakness, heart racing, fatigue 1 day after shot walked to neighbors house for Thanksgiving and felt the above symptoms. Ignored the symptoms for 2 weeks. Went to visit daughter and she called a cardiogist to evaluate. Diagnosed with a-fib. Never had a history of heart problems. Was put on 2 heart medications.(Diltiazem 180mg, Eliquis 5mg. Went into ER for a cardioversion. Returned to normal rhythm for only 2 days and back in afib. Went back to cardiologist who did an echocardiogram which showed afib, tachycardia, low ejection fracture 25%, Leakey mitral valve. Given another new medication Metoprol 25mg Amiodarone 200mg Told to stop taking Diliazem Going back home today where I live and made appointment for a cardiologist to continue my care. I currently still have fatigue, shortness of breath, weakness, lightheadedness, palpitations. Can't walk a few feet without needing to stop.
On June 24th I saw my eye DR and was diagnosed with retinal hemorrhage and then had some blood tests done with my PCD on June 28th 2021. I was placed on a Cholesterol lowering medication and then I still have further blood tests to do as well. I did not have any other symptoms or anything, it was all an incidental finding after a routine eye exam.
had both doses 3 years ago, developed shingles/ suspected Vaccination failure; have developed shingles; slight rash; pain was persistent, seek medical care; This case was reported by a consumer and described the occurrence of vaccination failure in a 72-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix and Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, rash and pain. On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the shingles, rash and pain were not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure, shingles, rash and pain to be related to Shingrix and Shingrix.     Additional Information: GSK receipt date: 10-Aug-2022 Reporter's comment: The patient was 72 years old and in good health. The patient had both doses of the shingrex vaccine three years ago. The patient had developed shingles and been diagnosed and treated by his/her primary health care professional. The patient had only a very slight rash, but pain was persistent enough to make him/her seek medical care. The patient was disappointed that the patient had shingles, trying to avoid it by getting the vaccine. On the other hand, the patient heard many accounts of serious and painful bouts of shingles, and he/she consider his/her case light most likely due to having the vaccine. Additional supportive information: This case was considered as suspected vaccination failure as details regarding time to onset, laboratory test confirming shingles were unknown at the time of reporting. The reporter consent to follow up was unknown.
THE PATIENT WAS GIVEN THE PFIZER VACCINE INSTEAD OF THE MODERNA VACCINE FOR HIS SECOND DOSE. FROM THE LAST TIME I SPOKE TO THE PATIENT HE HAS NOT EXPERIENCED ANY SIDE EFFECTS FROM THE ERROR
Pt recv vax on 3/29/99; on 3/30/99 pt exp turning blue, difficulty breathing
1st dose on 2019, hasn't received dose 2; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 73-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose of Shingrix received on 2nd April 2019, Batch Number :4257F,Expiry date:11th September 2021).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 06-APR-2022 Reporter's Comment: The reporter consented to follow up. Additional Supportive Information: Till the time of reporting the patient did not receive 2nd dose of Shingrix , which led to incomplete course of vaccination. The case had been linked to US2022061067, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022061067:Same reporter
This spontaneous report as received from a registered pharmacist refers to a 73 years old patient of unknown gender. On 15-JUL-2013 the patient was inadvertently vaccinated with an expired 0.65 ml dose of ZOSTAVAX (lot # 0618AE, expiration date: 23-JUN-2013), subcutaneously at unspecified locations. No adverse effects reported. The patient did not seek medical attention. Additional information has been requested.
Disruption to menstrual cycle, mastitis, shortness of breath, swelling of tongue, light headedness.
None- vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (None- vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported by reporter. No treatment information was reported.   This case was linked to MOD-2021-395985 (Patient Link).
Information has been received from a physician via Pfizer (manufacturer number 2017064371) referring to a patient of unknown age and gender. The patient's medical history, concurrent condition and concomitant therapy were not provided. On an unknown date, the patient was vaccinated with PNEUMOVAX 23 (dose, route, lot number and expiration date unknown) for prophylaxis. On an unknown date, the patient experienced a severe reaction to their last dose of PNEUMOVAX 23 a few years ago. The physician would like to administer PREVNAR 13 for the patient but wanted to know whether PREVNAR 13 would cause similar reaction to the patient. The physician wanted to know what would be the likelihood of a reaction to a patient who had already had this reaction to a PNEUMOVAX 23 in the past? The outcome of the event was unknown. The reporter considered adverse reaction to be related to PNEUMOVAX 23. Additional information has been requested.
sore arm; This is a spontaneous report received from a contactable consumer (patient) via Pfizer sponsored program . A female patient of unspecified age received first dose of BNT162B2(PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number: Unknown) via unknown route of administration on 13Apr2021 as a single dose for Covid-19 immunization. Medical history and concomitant medications were not reported. On 13Apr2021, the patient had sore arm. The outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Pt reportedly noted to be irritable then stiffed up & then became limp, pale & unresponsive for about 10 seconds; In ER witnessed episode of apnea lasting about 10 seconds assoc w/limpness & responding to stimulation;
Agitation, Diarrhea, Tachycardia, Tingling in upper extremities, started having carpopedal spasms, Pale, anxious. Narrative:  Patient brought over to the ER via gurney after receiving her covid vaccine. Patient was nearing the end of her 15" of observation when she felt her heart was racing. Initial VS was 123/78, HR 143 with saturations of 100%
VARIVAX vaccine was administered, I ordered immunization in error, believing it was childs 2nd shift. In fact, it was his third shot. No adverse reaction. No symptoms after shot. No consequences medically noted.
Patient fell down the stairs on 04/18/2021; EMT services found no pulse upon their arrival to the scene. Patient was transported to hospital and found to have several broken bones in neck and ultimately died on 04/18/2021 at the hospital. Patient tested positive for COVID-19 upon admission to hospital, despite being  fully vaccinated. Patient did not have any known symptoms of COVID-19; the death is not thought to be related to COVID-19.
Body aches, feet numb progressing to weakness inability to walk - Lumbar puncture high protein no cells - previously Guillain Barre diagnosed at 5 years age - currently treated with IVIG and improving.
HE WAS HOT, FLUSHING SWEATING 5 MINUTES AFTER RECEIVING THE VACCINE. ON SITE EMS RESPONDED. BP 163/76  HR 90. AFTER 10 MINUTES HE FELT FINE AND LEFT FOR HOME
Employee received Covid19 vaccine on 01/13/2021 at 8:30 am and at 9:30 am she began  having, pain and burning to her left arm at the sight of the vaccine.  Two days later she was unable to lift her left arm due to the severe pain which continues until now.
Rash on torso, back, arms, and legs. Also sore throat, fever, cough, tired. Treatment ok
Information has been received from a registered nurse concerning her 17 year old son (now 20 years old) who had an amoxicillin allergy, asthma and acne who on 6/17/2003 was vaccinated IM with a 0.5ml dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (lot 644576/1013M). Concomitant therapy included albuterol sulfate (Proventil) and tetracycline. The RN reported that on 6/27/2003, her son developed a sore throat, fever and swelling of his neck. On the same day, the patient went to ER and was subsequently hospitalized. A diagnosis of tonsillitis and pharyngitis was made. On 6/28/2003, the patient was discharged from the hospital to home with an antibiotic and ibuprofen. The RN was unclear as to when her son's symptoms resolved, but noted that her son had recovered from the tonsillitis and pharyngitis. The RN also indicated that some time after vaccination, her developed low hemoglobin and was subsequently diagnosed with anemia. She felt that the anemia was not related to vaccination with measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live. Additional information has been requested.
This is an initial spontaneous report from a contactable nurse, from an office, reporting on a patient. A 73-year-old male patient, who was a pharmacist, received PREVNAR 13 (Lot# L35183, expiration date 30Sep2016, and NDC# 0005197101) intramuscular at 0.5ml, single in his left deltoid on 15Apr2015. He did not receive any other vaccines or medications that day to their knowledge. The patient's medical history was not reported. The patient's concomitant medications were not reported. Patient reported that his left hand swelled up, he had a neurological type reaction, his leg wouldn't move to walk, he had no balance on his left side and it was almost a stroke like reaction. He did not state how long the symptoms lasted, or when they first appeared and he declined an appointment, when offered, to see the physician when they called and spoke to him on 20Apr2015. He told the office employee he was fine and just wanted his side effects reported to the manufacturer. The patient recovered from all the events.
Confirmed COVID-19 infection; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Confirmed COVID-19 infection) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for COVID-19 prophylaxis.    Concurrent medical conditions included Carcinoma brain and Drug allergy (drug name not specified).   On 18-Mar-2021, the patient received first dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (unknown route) 1 dosage form. On 18-Nov-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Apr-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2022, the patient experienced COVID-19 (Confirmed COVID-19 infection) (seriousness criterion medically significant). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 28-Jun-2022 to 02-Jul-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Confirmed COVID-19 infection) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2022, SARS-CoV-2 test: (Positive) Positive. On 02-Jul-2022, SARS-CoV-2 test: (Negative) Negative. On 08-Jul-2022, SARS-CoV-2 test: (Positive) Positive.         No concomitant medications were provided. On 02-Jul-2022 patient tested negative for COVID-19 test after Paxlovid treatment for 5 days. On an unspecified date in Jul-2022 (5 days after Paxlovid treatment), patient started experiencing symptoms of coughing, congestion and low-grade fever. On 08-Jul-2022 (6 days after negative test), patient tested positive for Covid-19 virus test. The patient was treated with guaifenesin (Mucinex) and cough medication. Action taken with Paxlovid was reported as withdrawn. Company comment:  This is an spontaneous case concerning a 53-year-old female  patient with medical history of brain Carcinoma who experienced the seriousness criterion medically significant event of COVID-19 (AESI), unknown days  after receiving 3rd. dose of mRNA-1273 vaccine. On July, 8, 2022, SARS-CoV-2 test was performed with positive result  and the patient received Paxlovid co-suspect drug for 5 days;  after stop it, SARS-CoV-2 test result was positive. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: Company comment:  This is an spontaneous case concerning a 53-year-old female  patient with medical history of brain Carcinoma who experienced the seriousness criterion medically significant event of COVID-19 (AESI), unknown days  after receiving 3rd. dose of mRNA-1273 vaccine. On July, 8, 2022, SARS-CoV-2 test was performed with positive result  and the patient received Paxlovid co-suspect drug for 5 days;  after stop it, SARS-CoV-2 test result was positive. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Pt presented at Medical Center ED, 01/12/2022,  with acute hypoxemic respiratory failure due to COVID-19. Pt had tested + for COVID 01/11/2022. Admitted.
PT came in with weakness, shortness of breath and cough for 4 days prior to coming in. PT is on remvesivir; cescriaxone, doxycycline PT is still in hospital
Burning rash from toes to torso; Itchy from bottom of feet, rash / itchy from toes to legs / red rash went up to torso, burning, itching; Bumps at site of rash / bumps where rash has occured; Burning sensation from rash; Bumps at site of rash / bumps where rash has occured; Burning sensation from rash; Itchy from bottom of feet, rash / itchy from toes to legs / red rash went up to torso, burning, itching; sore arm at injection site; This spontaneous case was reported by a consumer and describes the occurrence of the first episode of RASH PRURITIC (Itchy from bottom of feet, rash / itchy from toes to legs / red rash went up to torso, burning, itching), the first episode of RASH PAPULAR (Bumps at site of rash / bumps where rash has occured), the first episode of BURNING SENSATION (Burning sensation from rash), the second episode of RASH PRURITIC (Itchy from bottom of feet, rash / itchy from toes to legs / red rash went up to torso, burning, itching) and the second episode of RASH PAPULAR (Bumps at site of rash / bumps where rash has occured) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included ATORVASTATIN, HYDROCHLOROTHIAZIDE, METOPROLOL and ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced VACCINATION SITE PAIN (sore arm at injection site). On 12-Mar-2021, the patient experienced the first episode of RASH PRURITIC (Itchy from bottom of feet, rash / itchy from toes to legs / red rash went up to torso, burning, itching). On 13-Mar-2021, the patient experienced the first episode of RASH PAPULAR (Bumps at site of rash / bumps where rash has occured) and the first episode of BURNING SENSATION (Burning sensation from rash). On 14-Mar-2021, the patient experienced the second episode of RASH PRURITIC (Itchy from bottom of feet, rash / itchy from toes to legs / red rash went up to torso, burning, itching), the second episode of RASH PAPULAR (Bumps at site of rash / bumps where rash has occured) and the second episode of BURNING SENSATION (Burning sensation from rash). On 15-Mar-2021, the patient experienced RASH (Burning rash from toes to torso). The patient was treated with LORATADINE, PSEUDOEPHEDRINE HYDROCHLORIDE (BENADRYL 24 D) on 12-Mar-2021 at an unspecified dose and frequency. At the time of the report, last episode of RASH PRURITIC (Itchy from bottom of feet, rash / itchy from toes to legs / red rash went up to torso, burning, itching), the last episode of RASH PAPULAR (Bumps at site of rash / bumps where rash has occured), the last episode of BURNING SENSATION (Burning sensation from rash), RASH (Burning rash from toes to torso) and VACCINATION SITE PAIN (sore arm at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Developed Diverticulitus.   Abdominal pain, fever, cramping .   Ist vaccine does was 3/1/21.  Diverticulitus developed with first incident on 8/2021, then 1/8 2022 just after the booster vaccination, then most severe in May 2022.
Chest pains, trouble breathing, choking sensation, chronic burping. Given prescription Zantac for chronic burping.
Myalgia, Fever, UrticariaPruritus, Hx. chronic Urticaria developed hives 29 hours afterward. Also reports fatigue and pain at the insertion site.  Narrative: Employee reports history of chronic Urticaria. She developed hives 29 hours afterwards. She notified her allergist and was rx. hydroxyzine.
Patient received second dose Moderna vaccine at 11:40 and started to feel nauseous and warm at 1pm. Patient given crackers and water, she stated that she is diabetic and only had an orange for breakfast. 1:05 pm VS B/P144/68,HR 79 and 02 sat 95%.  1:07pm VS B/P 142/67, HR 77 and 02 sat 94%. Patient stated feeling better and attribute to not eating. More crackers and water given. 1:20pm VS B/P 138/71, HR 78 and 02 sat 96%. Patient stated feeling safe and comfortable to go home and get something to eat.  Patient received second dose Moderna vaccine at 11:40 and started to feel nauseous and warm at 1pm. Patient given crackers and water, she stated that she is diabetic and only had an orange for breakfast. 1:05 pm VS B/P144/68,HR 79 and 02 sat 95%.  1:07pm VS B/P 142/67, HR 77 and 02 sat 94%. Patient stated feeling better and attribute to not eating. More crackers and water given. 1:20pm VS B/P 138/71, HR 78 and 02 sat 96%. Patient stated feeling safe and comfortable to go home and get something to eat.